['ovarian cancer']
['apatinib', 'etoposide']

        Inclusion Criteria:

          -  Histologically or pathologically confirmed diagnosis of epithelial carcinoma of the
             ovary.

          -  Platinum resistant ovarian cancer (defined as relapsing within 6 months after the last
             administration of platinum-based chemotherapy) OR platinum refractory ovarian cancer
             (defined as progressing while on a platinum-based chemotherapy)

          -  At least treated with one line of platinum-based chemotherapy

          -  Female, age ≥18 years and ≤70 years, signed informed consent.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)
             1.1 version

          -  Patients must have a life expectancy of at least 3 months.

          -  Patients must have adequate organ function as defined by the following criteria:

               -  White blood cell count ≥ 3 x 10^9/L, Absolute neutrophil count (ANC) (≥ 1.5 x
                  10^9/L), Hemoglobin of ≥ 80 g/L, Platelets ≥ 70 x 10^9/L

               -  Total bilirubin ≤ 1 x upper limit of normal (ULN), AST and ALT ≤ 2 x ULN

               -  Serum creatinine ≤ 1 x ULN

        Exclusion Criteria:

          -  Had prior exposure to apatinib or has known allegies to any of the excipients.

          -  History of myocardial infarction, or unstable angina, or New York Heart Association
             (NYHA) Grade III-IV within 6 months prior to Day 1.

          -  Patients with QT interval prolongation

          -  Serious, non-healing wound, active ulcer, bowel obstruction.

          -  History of abdominal fistula or gastrointestinal perforation within 28 days prior to
             Day 1

          -  Evidence of bleeding diathesis or coagulopathy

          -  Inadequately controlled hypertension

          -  Major surgical procedure within 28 days prior to Day 1

          -  Symptomatic central nervous system (CNS) metastasis
      